Guardant and MSD are working collectively on the event of accompanying diagnostics
Guardant Well being has entered right into a multi-year strategic partnership settlement with Merck & Co (MSD) for the event of companion diagnostics.
The partnership may even give attention to the commercialization of novel most cancers therapies utilizing the Guardant Infinity Good platform.
Uncover B2B advertising and marketing that delivers
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
Extra info
MSD and Guardant intention to make the most of Guardant’s portfolio of liquid and tissue biopsy checks as assays for the previous’s world oncology scientific trials.
The businesses may even assess the potential for creating new oncology therapies utilizing Guardant’s liquid biopsy checks as companion diagnostics.
They may even collaborate on the worldwide commercialization of medicines and companion diagnostics, together with within the Asia Pacific, European Union (EU), UK and US markets.
Guardant Chairman and Co-CEO Helmy Eltoukhy stated: “This strategic partnership permits us to deliver the facility of the Infinity Good platform to a few of the most essential oncology applications at the moment in improvement.
“As biomarkers grow to be more and more essential within the alternative of therapies, our purpose is to make sure that each research has the molecular readability wanted to achieve the precise sufferers. This collaboration strengthens our shared dedication to accuracy, scale and quicker improvement of life-changing most cancers therapies.”
Guardant focuses on precision oncology by way of AI analytics, superior blood and tissue testing, and real-world knowledge.
The diagnostic checks deal with all levels of care, together with early screening, monitoring for recurrence in early-stage illness and details about therapy selections for superior most cancers.
In December 2025, Guardant partnered with AI expertise firm Trial Library to enhance entry to most cancers scientific trials within the US by integrating precision oncology diagnostics with an AI-powered affected person matching platform.
This partnership goals to extend trial participation amongst various and underserved affected person teams by combining genomic knowledge with customized assist and navigation providers.
